KANSAS CITY — Familiar ingredients are likely to be selected by formulators developing products designed to appeal to users of GLP-1 agonist medications. These consumers tend to seek nutrient ...

Compared with nonuse, GLP-1RA and thiazolidinedione combination therapy reduced risks for all-cause and cardiovascular mortality in type 2 diabetes. The combination of a glucagon-like peptide 1 ...

These medications mimic a gut hormone called GLP-1 (glucagon-like peptide-1), known for its remarkable ability to reduce appetite, balance blood sugar and trigger fat burning. But what if your ...

Findings for matched groups of patients with obesity and diabetes taking first-generation GLP-1 RA or undergoing bariatric metabolic surgery. (HealthDay News) — Glucagon-like peptide-1 receptor ...

In recent years, Kessler has lost considerable weight himself with the help of the new GLP-1 drugs. He describes his weight loss and analyzes the drugs and their potential societal impact in his ...

Scientists do not fully understand why response to GLP-1s varies so widely among people prescribed them. Some benefits of GLP-1s occur independently of weight loss, so multiple factors are likely ...

GLP-1 receptor agonists (GLP-1 RAs), medications that help control type 2 diabetes and obesity, can have a profound impact on physical wellness – but what about mental health? Some examples of ...

The National Institutes of Health (NIH) published research in June 2024 that considered the correlation between semaglutide therapy and "exacerbating mood disturbances." The study highlighted the ...

Some even believe that the new GLP-1 drugs are playing a direct role in reducing demand for its products. In this article, I will give you my reasons why I believe these two factors are not ...

At the time, markets were attempting to figure out if so-called GLP-1 class drugs like Wegovy would dent the need for common diabetes treatments like insulin or even diminish incidence of the ...

It has also partnered with Novo Nordisk to expand access to GLP-1 medications. Other loopholes to the deadline are allowing companies to make and sell slightly different versions from the FDA ...

Primary care practices are seeing an uptick in patients inquiring about glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications due to both media hype and sizzle-reel stories they see on ...